Presentation is loading. Please wait.

Presentation is loading. Please wait.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:1388-1394.

Published byMariah Douglas Modified over 6 years ago

Similar presentations

Presentation on theme: "Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:1388-1394."— Presentation transcript:

1 Characteristics of the Folic Acid and Placebo Groups at the Start of the Study
J. Durga et al. Arch Intern Med. 2005;165:

2 Concentrations of Serum Folate, Plasma Homocysteine, and Inflammatory Markers After 1-Year Treatment With Folic Acid or Placebo J. Durga et al. Arch Intern Med. 2005;165:

3 Summary of Randomized Controlled Trials Investigating Effect of Folic Acid on Vascular Disease End Points or Surrogate Markers of Vascular Disease Risk J. Durga et al. Arch Intern Med. 2005;165:

Download ppt "Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:1388-1394."

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345:1291-7. Incidence of CV events in women.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
Vitamins - what is the evidence? Rohan Subasinghe.

Vitamins - what is the evidence? Rohan Subasinghe.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.

1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.
Mary Hannon-Fletcher Micronutrient supplementation in haemodialysis patient enhances folate levels and reduces homocysteine 4th Annual Translational Medicine.

Mary Hannon-Fletcher Micronutrient supplementation in haemodialysis patient enhances folate levels and reduces homocysteine 4th Annual Translational Medicine.
Characteristics of 3921 Men Seen by a Primary Care Provider Steven A. Grover, et al, Arch Intern Med. 2005;166:213-219.

Characteristics of 3921 Men Seen by a Primary Care Provider Steven A. Grover, et al, Arch Intern Med. 2005;166:
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:2184- 92.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
What is the Minimum Effective Dose of Folic Acid for Preventing NTDs? James L. Mills, M.D., M.S. Caroline Signore, M.D. NICHD.

What is the Minimum Effective Dose of Folic Acid for Preventing NTDs? James L. Mills, M.D., M.S. Caroline Signore, M.D. NICHD.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Shalev V, et al. Arch Intern Med 2009; 169:260-268.

Shalev V, et al. Arch Intern Med 2009; 169:
Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Similar presentations

Ads by Google